Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04101877 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Sahlgrenska Anti-VEGF Study

Study acronym: SAHLVE
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Sep 2024 to Oct 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Sep 2024 to May 2027
    • Site details revised
    v7
  2. 2 versions Re-verified since Apr 26, 2022, no change to tracked fieldsv5-v6
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2020 to Sep 3, 2020
    • Site details revised
    v4
  4. Primary and study completion dates: Sep 2023 to Sep 2024
    • Start date: Nov 2019 to Sep 2020
    v3
  5. Start date: Sep 2019 to Nov 2019v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study investigates whether patients treated for neovascular (wet) age-related macular degeneration (AMD), with intravitreal injection with bevacizumab (Avastin) after two years need more injections with retained therapy response compared to patients being treated with intravitreal injection with aflibercept (Eylea). The study also aims to evaluate if there is a difference in best-corrected visual acuity, macular thickness, recurrence interval, durability, cost efficiency, as well as vision-related quality of life.
Trial Details
NCT Number NCT04101877
Lead Sponsor Vastra Gotaland Region
Conditions
(from sponsor)		 Neovascular Age-related Macular Degeneration
Enrollment 402 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov